

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC.,  
Petitioner

v.

QUALICAPS CO., LTD,  
Patent Owner

---

Case IPR2017-00203  
Patent 6,649,180

---

**PATENT OWNER'S UPDATED EXHIBIT LIST**

DC: 6428538-7

## LIST OF EXHIBITS

EXHIBIT	DESCRIPTION
Ex. 2001	HARD CAPSULES (K. Ridgway ed., 1987)
Ex. 2002	Toshihiro Ogura, Yoshihiro Furuya, & Seinosuke Matsuura, <i>HPMC Capsules — An Alternative to Gelatin</i> , 20(11) J. PHARM. TECH. EUROPE 32 (November 1998)
Ex. 2003	THE HANDBOOK OF PHARMACEUTICAL EXCIPIENTS (“HPE”) Second Edition 229–32 (Ainley Wade and Paul J. Weller, eds., 1994)
Ex. 2004	Jae-Hwang Lee, <i>et al.</i> , <i>Specific PCR assays to determine bovine, porcine, fish and plant origin of gelatin capsules of dietary supplements</i> , 211 FOOD CHEMISTRY 253 (2016)
Ex. 2005	Federal Standard No. 285A, <i>Capsules (For Medicinal Purposes)</i> (October 19, 1976)
Ex. 2006	E. Bradbury & C. Martin, <i>The effect of temperature of preparation on the mechanical properties and structure of gelatin films</i> , 214 PROC. R. SOC. LONDON SERIES A 183 (1952)
Ex. 2007	U.S. Pat. No. 2,526,683 (issued Oct. 24, 1950 to Murphy)
Ex. 2008	U.S. Pat. No. 2,810,659 (issued Oct. 22, 1957 to Greminger, <i>et al.</i> )
Ex. 2009	<i>intentionally left blank</i>
Ex. 2010	J. C. Stone, <i>Objective Visual Evaluation of the Relative Content of Major and Minor Defects in Tablets and Capsules</i> , 59(9) J. PHARM. SCI. 1364 (1970)
Ex. 2011	I. H. Coopes, <i>Structure Formation in Gelatin Films</i> , PHOTOGRAPHIC GELATIN II, PROCEEDINGS OF THE ROYAL PHOTOGRAPHIC SOCIETY SYMPOSIUM 121 (R. J. Cox, ed., 1974)
Ex. 2012	J. E. Jolley, <i>The Microstructure of Photographic Gelatin Binders</i> , 14(3) PHOTOGR. SCI. ENG’G 169 (1970)
Ex. 2013	George A. Digenis, Thomas B. Gold, & Vinod P. Shah, <i>Cross-Linking of Gelatin Capsules and Its Relevance to Their In Vitro-In Vivo Performance</i> , 83(7) J. PHARM. SCI. 915 (1994)

EXHIBIT	DESCRIPTION
Ex. 2014	James Hogan, <i>et al.</i> , <i>Investigations into the Relationship Between Drug Properties, Filling, and the Release of Drugs from Hard Gelatin Capsules Using Multivariate Statistical Analysis</i> , 13(6) PHARM. RES. 944 (1996)
Ex. 2015	THE UNITED STATES PHARMACOPOEIA, at 774– 76 (1994)
Ex. 2016	THE JAPANESE PHARMACOPOEIA, at i–vii; 750–51, 800–804 (13th ed. 1996)
Ex. 2017	DOW METHOCCEL CELLULOSE ETHERS HANDBOOK (1978) [sp. corrected]
Ex. 2018	Jaime Curtis-Fisk, <i>et al.</i> , <i>Effect of Formulation Conditions on Hypromellose Performance Properties in Films Used for Capsules and Tablet Coatings</i> , 13(4) AAPS PHARMSciTECH 1170 (December 2012)
Ex. 2019	Linda Felton, <i>Film Coating of Oral Solid Dosage Forms</i> , in ENCYCLOPEDIA OF PHARMACEUTICAL TECHNOLOGY, at 1729–47 (J. Swabrick ed., 3rd ed., 2007)
Ex. 2020	U.S. Pat. No. 4,001,211 (issued Jan. 4, 1977 to Sarkar)
Ex. 2021	Document comparison by Workshare Compare software: comparison of Petition and Declaration of Arthur H. Kibbe
Ex. 2022	U.S. Pat. No. 5,431,917 (issued Jul. 11, 1995 to Yamamoto, <i>et al.</i> )
Ex. 2023	U.S. Pat. No. 6,326,026 (issued Dec. 4, 2001 to Parekh, <i>et al.</i> )
Ex. 2024	U.S. Pat. No. 6,228,416 (issued May 8, 2001 to Reibert, <i>et al.</i> )
Ex. 2025	U.S. Pat. No. 4,365,060 (issued Dec. 21, 1982 to Onda, <i>et al.</i> )
Ex. 2026	Declaration of Megan P. Keane in Support of Patent Owner’s Motion for Admission <i>Pro Hac Vice</i> of Megan P. Keane Under 37 C.F.R. § 42.10
Ex. 2027	Declaration of Michael N. Kennedy in Support of Patent Owner’s Motion for Admission <i>Pro Hac Vice</i> of Michael N. Kennedy Under 37 C.F.R. § 42.10
Ex. 2028	Declaration of Jason T. McConville, Ph.D. with <i>cv</i> and list of prior consulting work
Ex. 2029	Transcript, Deposition of Arthur H. Kibbe, Ph.D. (June 16, 2017)

EXHIBIT	DESCRIPTION
Ex. 2030	<i>Torrent Pharm. Ltd v. Novartis AG</i> , IPR2014-00784, Ex. 1028 (Transcript, Deposition of Arthur H. Kibbe, Ph.D. (March 25, 2015))
Ex. 2031	<i>Torrent Pharm. Ltd v. Novartis AG</i> , IPR2014-00784, Ex. 2058 (comparison between declarations of Dr. Kibbe and Dr. Kent)
Ex. 2032	<i>Torrent Pharm. Ltd v. Novartis AG</i> , IPR2014-00784, Paper 112 (Final Written Decision (Sept. 24, 2015))
Ex. 2033	<i>Gray Square Pharm, LLC v. Pozen, Inc.</i> , IPR2016-00191, Paper 10 (Decision Denying Institution (May 6, 2016))
Ex. 2034	<i>Dr. Reddy's Labs., Inc. v. Pozen Inc.</i> , IPR2015-00802, Paper 28 (Decision Denying Institution (Oct. 9, 2015))
Ex. 2035	DOW METHOCEL CELLULOSE ETHERS TECHNICAL HANDBOOK (1991)
Ex. 2036	R.C. Rowe, <i>The adhesion of film coatings to table surfaces - the effect of some direct compression excipients and lubricants</i> , 29 J. PHARM. PHARMAC. 723-26 (1977)
Ex. 2037	R.C. Rowe, <i>The molecular weight and molecular weight distribution of hydroxypropyl methylcellulose used in the film coating of tablets</i> , 32 J. PHARM. PHARMACOL. 116-19 (1980)
Ex. 2038	Gilbert Banker, <i>et al.</i> , <i>Evaluation of hydroxypropyl cellulose and hydroxypopyl methyl cellulose as aqueous based film coatings</i> , 7(6) DRUG DEV. IND. PHARM. 693-716 (1981)
Ex. 2039	A.O. Okhamafe, <i>et al.</i> , <i>Moisture permeation mechanism of some aqueous-based film coats</i> , 34(Suppl) J. PHARM. PHARMACOL 53P (1982)
Ex. 2040	U.S. Pat. No. 4,816,298 (iss. Mar. 28, 1989 to Alderman, <i>et al.</i> )
Ex. 2041	U.S. Pat. No. 4,916,161 (iss. Apr. 10, 1990 to Patell)
Ex. 2042	R.C. Rowe, <i>Materials used in the film coating of oral dosage forms</i> , in MATERIALS USED IN PHARMACEUTICAL FORMULATION, at 1-36 (A.T. Florence, ed. 1984)
Ex. 2043	M.C. Bonferoni, <i>et al.</i> , <i>A characterization of the three HPMC substitution grades: rheological properties and dissolution behaviour</i> , 13TH PHARMACEUTICAL TECHNOL. CONFERENCE, VOL. 1 (Strasbourg, France Apr. 12, 1994)

EXHIBIT	DESCRIPTION
Ex. 2044	<i>ASHP guidelines for selecting pharmaceutical manufacturers and suppliers</i> , 48(3) AM. J. HOSP. PHARM. 523-24 (1993)
Ex. 2045	Karen Mitchell, <i>et al.</i> , <i>The influence of additives on the cloud point, disintegration and dissolution of hydroxypropylmethylcellulose gels and matrix tablets</i> , 66 INT'L J. PHARM. 233-42 (1990)
Ex. 2046	U.S. Pat. No. 5,756,036 (iss. May 26, 1998 to Grosswald, <i>et al.</i> )
Ex. 2047	U.S. Pharmacopoeia, Ch. 1151, 4433–4440 (rev. 23d, 8th Supp. 1998)
Ex. 2048	Joseph Grover, <i>Methylcellulose and Its Derivatives</i> , Chap. 18 in INDUSTRIAL GUMS: POLYSACCHARIDES AND THEIR DERIVATIVES, at 475-504 (Roy Whistler & James BeMiller, eds. 3d ed. 1993)
Ex. 2049	A.C. Shah, <i>et al.</i> , <i>Gel-matrix systems exhibiting bimodal controlled release for oral drug delivery</i> , 9 J. CONTROL. RELEASE 169-75 (1989)
Ex. 2050	T.C. Dahl, <i>et al.</i> , <i>Influence of physico-chemical properties of hydroxypropyl methylcellulose on naproxen release from sustained release matrix tablets</i> , 14 J. CONTROL. RELEASE 1-10 (1990)
Ex. 2051	J.E. Hogan, <i>Hydroxypropylmethylcellulose sustained release technology</i> , 15(6&7) DRUG. DEV. IND. PHARM. 975-99 (1989)
Ex. 2052	Front Matter for Ex. 2036, R.C. Rowe, <i>The adhesion of film coatings to table surfaces - the effect of some direct compression excipients and lubricants</i> , 29 J. PHARM. PHARMAC. 723-26 (1977) (served, but not filed, August 11, 2017)
Ex. 2053	Front Matter for Ex. 2037, R.C. Rowe, <i>The molecular weight and molecular weight distribution of hydroxypropyl methylcellulose used in the film coating of tablets</i> , 32 J. PHARM. PHARMACOL. 116-19 (1980) (served, but not filed, August 11, 2017)
Ex. 2054	Front Matter for Ex. 2038, Gilbert Banker, <i>et al.</i> , <i>Evaluation of hydroxypropyl cellulose and hydroxypopyl methyl cellulose as aqueous based film coatings</i> , 7(6) DRUG DEV. IND. PHARM. 693-716 (1981) (served, but not filed, August 11, 2017)

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.